Allergy to protamine.
Review published in Clinical reviews in allergy (1991)
Abstract
Recent advances in medicine, such as cardiac catheterization, phoresis, dialysis, and cardiopulmonary bypass technology, have increased the need for heparin anticoagulation. To antagonize heparin's effect and prevent hemorrhagic complications after the procedure, protamine has likewise been used more frequently. With its increased use have come increased reports of adverse protamine reactions consisting of rash, urticaria, elevation of pulmonary artery pressure, systemic hypotension, and, at times, death. The elevation of pulmonary artery pressure, which appears to be a rather common occurrence in animals, may be an isolated finding without clinical consequences in humans. However, this pulmonary vasoconstriction may, when severe, lead to acute right-sided heart failure and systemic hypotension. Other protamine reactions involve a decrease in systemic vascular resistance and systemic hypotension without changes in pulmonary artery pressure. Causes of acute protamine reactions may involve the generation of anaphyatoxins and prostanoids either from protamine-heparin complexes or complement-fixing antiprotamine IgG antibodies, from inhibition of plasma Carboxypeptidase N, from crosslinking of cell-surface antiprotamine IgE on mast cells and basophils with subsequent mediator release, or from potentiation of IgE-mediated release of histamine through a polycationin-recognition site. Although we have come a long way in understanding the mechanisms by which protamine can cause its ill effects in humans, more work is clearly needed to define, in prospective studies, the incidence of and risk factors for protamine reactions in various patient groups, and to delineate more clearly which mechanisms are involved in each clinical type of acute protamine reaction. Hopefully, this will lead to strategies and protamine alternatives that will prevent or diminish, in frequency or severity, adverse protamine reactions. Alternatively, a clearer picture of the risk factors important for protamine reactions and the predictive value of diagnostic tests (e.g., protamine IgE antibody) can also minimize the clinical impact of this increasingly common adverse event.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
Recent advances in medicine, such as cardiac catheterization, phoresis, dialysis, and cardiopulmonary bypass technology, have increased the need for heparin anticoagulation. To antagonize heparin's effect and prevent hemorrhagic complications after the procedure, protamine has likewise been used more frequently.
Warum dies für die Hirudotherapie relevant ist
Diese Übersichtsarbeit untersuchte Nebenwirkungen von Protamin, dem Arzneimittel, das häufig zur Aufhebung der Heparin-Antikoagulation nach Eingriffen wie Herzkatheteruntersuchung, Dialyse und kardiopulmonalem Bypass verwendet wird. Die Übersicht beschreibt mehrere Mechanismen von Protamin-Reaktionen – einschließlich komplementfixierender Anti-Protamin-IgG-Antikörper, IgE-vermittelter Freisetzung von Mediatoren aus Mastzellen und Basophilen, Anaphylatoxin-Generierung und pulmonaler Vasokonstriktion – und weist auf die Notwendigkeit prospektiver Studien hin, um Inzidenz, Risikofaktoren und Protamin-Alternativen zu definieren. Dies ist indirekt relevant für das Gebiet von ASH, da der klinische Bedarf an Protamin-Alternativen sich mit dem Interesse an direkten Thrombininhibitoren der Hirudin-Klasse überschneidet, die keine Protamin-Antagonisierung erfordern und somit diese Risiken unerwünschter Reaktionen umgehen könnten. Einschränkung: Die Übersicht diskutiert keine Blutegel, keine Hirudotherapie und kein Hirudin; ihre Relevanz für das Gebiet von ASH ist indirekt und basiert lediglich auf dem breiteren klinischen Kontext der Herausforderungen im Antikoagulationsmanagement.
Zitation
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 28, 2026 · Letzte Aktualisierung der Website: 18. Juni 2026